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Background: Bravecto™ (fluralaner; MSD Animal Health) is a novel systemic ectoparasiticide for dogs providing
long-acting flea- and tick-control after a single oral dose. Scalibor™ Protectorband (deltamethrin; MSD Animal
Health) is a collar often used to reduce sandfly feeding for leishmaniasis prevention. This study investigated the
safety of the concurrent use of BravectoTM and ScaliborTM Protectorband at the recommended dosage regimens.
Findings: Throughout the study period of 24 weeks, there were no clinical findings related to the concurrent
treatment with Bravecto™ in dogs fitted with Scalibor™ Protectorband at the recommended dosage regimen.
Conclusions: Concurrent treatment with Bravecto™ in dogs fitted with Scalibor™ Protectorband is well tolerated.
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Bravecto™ (active ingredient: fluralaner) is a new system-
ically administered insecticidal and acaricidal product.
Numerous studies including a recent field study in dogs
have shown that a single fluralaner dose administered
orally as chewable tablet provides flea and tick control
for twelve weeks [1].
Scalibor™ Protectorband (active ingredient: deltameth-
rin) is a collar that provides an anti-feeding effect for up
to 6 months against ectoparasites including phleboto-
mine sandflies and mosquitos [2]. Sandflies are the vec-
tors of Leishmania spp.
To protect dogs from tick and flea infestations, as well
as from sandfly bites, both products may be administered
concurrently. This study was conducted in healthy dogs
to confirm the safety of the concurrent use of Bravecto™
and Scalibor™ Protectorband at the recommended dosage
regimens [2,3].
Methods
The study was conducted in Queensland, Australia, after
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Fisheries and Forestry, approval no. CA 2013/06/701).
Twenty healthy male and female dogs of various breeds
were randomly assigned to two study groups. On day 0,
dogs of the treatment group were fitted a Scalibor™ Pro-
tectorband collar and received a Bravecto™ (fluralaner)
chewable tablet while dogs of the control group remained
un-treated. Dogs of the treatment group were adminis-
tered Bravecto™ on a second occasion on day 84. The ac-
tual fluralaner doses administered were 27 - 50 mg/kg
BW. As indicated on the product leaflet dogs were fed
around the time of Bravecto™ treatment [3], since bioavail-
ability of fluralaner is higher in fed dogs [4]. All dogs were
carefully observed for general health during the first hour
following treatment and were examined by a veterinarian
at 6, 12, 24, 32, 48, 56, 72, 80 hours, and 4, 6, 8, 10 days
after each Bravecto™ treatment. The veterinarian exam-
ined for abnormalities in behaviour, coat and skin inclu-
ding collar administration site, locomotion, respiration,
eyes, ears, nose, oral cavity, mucous membranes, capillary
refill time, pulse palpation, vomitus, feces and urine as
present in pen, and any other visible abnormalities. The
clinical observations were scheduled to cover the period
of highest systemic fluralaner exposure [5] and the time
Scalibor™ Protectorband delivers the full efficacy following
application [2]. Therefore, clinical signs associated withl Ltd. This is an Open Access article distributed under the terms of the Creative
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these time points. Veterinary examinations continued
on study days 27, 55, 83, 111, 139 and 168 (examinations
included assessment of abnormalities in behaviour, loco-
motion, auscultation of heart and lung, heart rate, respira-
tory rate, pulse palpation, mucous membranes, capillary
refill time, abdominal palpation, superficial lymph nodes,
skin including collar administration site, eyes, pupils, ears,
nose, mouth, teeth, tongue, anus, vagina, penile orifice,
mammary glands, testicles, joints, feet, pads, rectal tem-
perature) and general health observations (observations of
dogs in their pen including check of collar administration
site) were performed on all dogs once to twice daily. The
veterinary study investigator assessed all parameters re-
corded and all clinical findings for their relationship to
Bravecto™ and/or Scalibor™ treatment. Body weights were
recorded weekly.
At monthly intervals dogs in both groups received mo-
xidectin orally at a minimum dose of 3 mcg/kg BW for
heartworm prevention. No clinical findings were observed
in treatment or control group dogs associated with moxi-
dectin administration.
Results and discussion
Throughout the 24-week study period, there were no
clinical findings related to the concurrent treatment with
Bravecto™ in dogs fitted with Scalibor™ Protectorband.
In the treatment group single incidences of minor and
transient localized skin reactions were observed at the
collar application site, which were considered to be due
to the mechanical influence of the collar. These observa-
tions are not unexpected in dogs wearing collars and are
consistent with the product leaflet [2]; none of the col-
lars needed to be removed. Such findings have not been
reported in studies where only Bravecto™ was adminis-
tered [1,6]. No other clinical findings related to the
use of either product alone, or to the concurrent use
of Bravecto™ and Scalibor™ Protectorband were observed.
There were no obvious changes in group mean body-
weights during the study (the mean body weight of treated
group was 17.3 kg pre-treatment on day −1 and 18.1 kg
on day 168).
Conclusion
Concurrent treatment with Bravecto™ (fluralaner) in dogs
fitted with Scalibor™ Protectorband (deltamethrin) is well
tolerated.
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